Towards an assessment of toxicity in the treatment of ovarian cancer.
Using data from a randomised clinical trial of two platinum drugs at The Royal Marsden Hospital, London, a descriptive model of toxicity has been developed and tested. Toxicity manifests itself in reducing the effectiveness of different body processes; five were selected in this study as being most critical. The model summarises and combines data from these five sites in terms of a clinician's assessment of the associated risk to the patient. It is hoped that the approach will help clarify toxicity information for use in patient management decision-making and in the reporting of clinical trial results.
Dones
L
L
Department of Statistical Science, University College London, England.
Wiltshaw
E
E
Birkhead
B G
BG
Jackson
R R
RR
D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D001853:Bone Marrow / Q000187:drug effects; D016190:Carboplatin; D002945:Cisplatin / Q000627:therapeutic use / Q000633:toxicity*; D002986:Clinical Trials as Topic; D004064:Digestive System / Q000187:drug effects; D007758:Ear, Inner / Q000187:drug effects; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008954:Models, Biological; D009944:Organoplatinum Compounds / Q000627:therapeutic use / Q000633:toxicity*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D010525:Peripheral Nerves / Q000187:drug effects; D011897:Random Allocation; D012307:Risk Factors
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D016190:Carboplatin; D002945:Cisplatin